Correction: Balleza Alejandri et al. Empagliflozin and Dapagliflozin Improve Endothelial Function in Mexican Patients with Type 2 Diabetes Mellitus: A Double-Blind Clinical Trial. <i>J. Cardiovasc. Dev. Dis.</i> 2024, <i>11</i>, 182

Documenti analoghi

• Comparison of Extraglycemic effects of Dapagliflozin and Empagliflozin
  di: Haroon Aziz, et al.
  Pubblicazione: (2023-06-01)
• Gliflozins in Practice: Real-Life Use of Dapagliflozin and Empagliflozin in HFrEF Versus Clinical Trial Data
  di: Massimo Mapelli, et al.
  Pubblicazione: (2026-03-01)
• Effects of Empagliflozin and Dapagliflozin in alleviating cardiac fibrosis through SIRT6-mediated oxidative stress reduction
  di: Hong-xia Ma, et al.
  Pubblicazione: (2024-12-01)
• Divergent electrophysiologic action of dapagliflozin and empagliflozin on ventricular and atrial tachyarrhythmias in isolated rabbit hearts
  di: Julian Wolfes, et al.
  Pubblicazione: (2024-02-01)
• Cost-utility analysis of empagliflozin compared with dapagliflozin in patients with type 2 diabetes in China
  di: Huiyuan Zhang, et al.
  Pubblicazione: (2025-07-01)